Mitsubishi UFJ Trust & Banking Corp Decreases Holdings in Insulet Corporation $PODD

Mitsubishi UFJ Trust & Banking Corp reduced its stake in Insulet Corporation (NASDAQ:PODD) by 63.4% during the second quarter, according to its most recent filing with the SEC. The fund owned 33,622 shares of the medical instruments supplier’s stock after selling 58,344 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp’s holdings in Insulet were worth $10,563,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the stock. American Century Companies Inc. boosted its stake in Insulet by 34.8% in the first quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier’s stock valued at $302,686,000 after acquiring an additional 297,734 shares during the last quarter. Nuveen LLC bought a new stake in shares of Insulet in the 1st quarter worth approximately $74,163,000. Kayne Anderson Rudnick Investment Management LLC lifted its stake in Insulet by 1,316.5% in the first quarter. Kayne Anderson Rudnick Investment Management LLC now owns 193,511 shares of the medical instruments supplier’s stock valued at $50,818,000 after purchasing an additional 179,850 shares during the last quarter. Vanguard Group Inc. grew its holdings in Insulet by 2.1% during the first quarter. Vanguard Group Inc. now owns 8,668,952 shares of the medical instruments supplier’s stock valued at $2,276,553,000 after purchasing an additional 178,976 shares during the period. Finally, AustralianSuper Pty Ltd grew its holdings in Insulet by 487.5% during the second quarter. AustralianSuper Pty Ltd now owns 205,168 shares of the medical instruments supplier’s stock valued at $64,460,000 after purchasing an additional 170,247 shares during the period.

Insiders Place Their Bets

In related news, SVP Prem Singh sold 687 shares of Insulet stock in a transaction on Monday, September 8th. The stock was sold at an average price of $347.49, for a total transaction of $238,725.63. Following the completion of the sale, the senior vice president owned 3,456 shares of the company’s stock, valued at approximately $1,200,925.44. This trade represents a 16.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Laetitia Cousin sold 797 shares of the business’s stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $348.81, for a total value of $278,001.57. Following the transaction, the senior vice president owned 3,890 shares of the company’s stock, valued at approximately $1,356,870.90. The trade was a 17.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 0.39% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on PODD shares. Canaccord Genuity Group upped their price target on Insulet from $399.00 to $428.00 and gave the company a “buy” rating in a research report on Friday, November 7th. Piper Sandler boosted their price objective on Insulet from $320.00 to $360.00 and gave the company an “overweight” rating in a research note on Tuesday, September 16th. Rothschild & Co Redburn upped their price objective on shares of Insulet from $350.00 to $370.00 and gave the company a “buy” rating in a report on Friday, October 3rd. Oppenheimer increased their target price on shares of Insulet from $324.00 to $365.00 and gave the stock an “outperform” rating in a research report on Monday, September 8th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Insulet in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $374.10.

Insulet Trading Up 0.0%

Shares of Insulet stock opened at $332.70 on Monday. The company’s 50-day moving average price is $323.58 and its 200-day moving average price is $312.88. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64. Insulet Corporation has a 12-month low of $230.05 and a 12-month high of $353.50. The company has a market cap of $23.40 billion, a price-to-earnings ratio of 101.12, a PEG ratio of 2.64 and a beta of 1.39.

Insulet (NASDAQ:PODD) last posted its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share for the quarter, topping analysts’ consensus estimates of $1.13 by $0.11. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The business had revenue of $521.70 million for the quarter, compared to analyst estimates of $678.70 million. During the same quarter in the prior year, the firm posted $1.08 EPS. Insulet’s revenue was up 29.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, equities analysts expect that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.